Table 1.
Clinical Characteristics of the Study Cohort
| Characteristics of EOT | Total (n=122) | Sustained Response (n=78, 63.9%) | Clinical Relapse (n=44, 36.1%) | p-value |
|---|---|---|---|---|
| Age (years) | 34 (29–40) | 33 (22–39) | 36.5 (31–41) | 0.109 |
| Male (%) | 95 (77.9%) | 60 (76.9%) | 35 (79.5%) | 0.738 |
| Antiviral regiment | 0.168 | |||
| ETV/TDF (%) | 71 (58.2%) | 49 (62.8%) | 22 (50%) | |
| Others (%) | 51 (41.8%) | 29 (37.2%) | 22 (50%) | |
| Treatment duration, (years) | 4.7 (3.2–6.2) | 4.3 (2.9–6.4) | 5.0 (3.7–6.0) | 0.398 |
| Consolidation treatment duration (years) | 2.5 (1.3–3.6) | 3.0 (1.5–3.9) | 2.0 (1.2–3.4) | 0.125 |
| ALT level (ULN) | 0.42 (0.34–0.54) | 0.50 (0.38–0.68) | 0.48 (0.43–0.59) | 0.324 |
| HBV DNA (log10 IU/mL) | UD | UD | UD | - |
| HBsAg (log10 IU/mL) | 2.52±1.11 | 2.35±1.20 | 2.82±0.85 | 0.025 |
| <100 IU/mL (%) | 31 (25.4%) | 27 (34.6%) | 4 (9.15%) | <0.001 |
| ≥100 IU/mL (%) | 91 (74.6%) | 51 (65.4%) | 40 (90.9%) | |
| HBcrAg (log10 U/mL) | 3.80±0.83 | 3.59±0.82 | 4.15±0.72 | <0.001 |
| Liver siffness value (kPa) | 5.3 (4.5–6.2) | 5.3 (4.6–6.0) | 5.8 (4.8–6.6) | 0.149 |
Notes: Variables are expressed as means ± SD, median (interquartile range), or n (%).
Abbreviations: ALT, alanine aminotransferase; EOT, end of treatment; ETV, entecavir; TDF, tenofovir; ULN, upper limit of normal; HBeAg, hepatitis B envelope antigen; HBsAg, hepatitis B surface antigen; HBcrAg, hepatitis B core-relative antigen; UD, undetectable (<20 IU/mL).